Literature DB >> 6573159

Pulmonary artery growth during treatment with oral prostaglandin E2 in ductus dependent cyanotic congenital heart disease.

P MacMahon, P F Gorham, R Arnold, J L Wilkinson, D I Hamilton.   

Abstract

Growth of the pulmonary arteries was assessed in 11 patients with cyanotic congenital heart disease treated with oral prostaglandin E2. Each patient was dependent on patency of the ductus arteriosus for maintenance of the pulmonary circulation. Measurements were made initially from angiographic data obtained in the neonatal period. Subsequent assessments were made at the time of surgery after an interval of 2-8 months, during which time all the infants had gained weight normally. Comparisons were made with data obtained from 13 normal necropsy specimens. In only 4 of the 11 patients had the pulmonary arteries grown appreciably during the treatment period. In 2 patients no growth occurred, while in 5 patients the pulmonary arteries had actually become smaller. It had been hoped that the pulmonary arteries would grow in all 11 patients during this period, facilitating later surgical intervention. In patients with ductus-dependent cyanotic congenital heart disease, the prolonged use of oral prostaglandin E2 should be restricted to patients in whom the pulmonary arteries are too small to allow a palliative operation to be performed initially.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6573159      PMCID: PMC1627845          DOI: 10.1136/adc.58.3.187

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  2 in total

1.  Outcome of treatment for neonates referred to a supraregional cardiac centre 1976-78.

Authors:  D F Dickinson; R Arnold; J L Wilkinson
Journal:  Arch Dis Child       Date:  1982-05       Impact factor: 3.791

2.  Oral prostaglandin E2 in ductus-dependent pulmonary circulation.

Authors:  E D Silove; J Y Coe; M F Shiu; J D Brunt; A J Page; S P Singh; M D Mitchell
Journal:  Circulation       Date:  1981-03       Impact factor: 29.690

  2 in total
  1 in total

1.  Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.

Authors:  E D Silove; D G Roberts; J V de Giovanni
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.